ANZCTR - Registration

Please note that the ANZCTR website will be unavailable from 1pm to 2pm on Monday the 29th of April for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers

Trial registered on ANZCTR

Registration number

ACTRN12617001325392

Ethics application status

Approved

Date submitted

12/09/2017

Date registered

15/09/2017

Date last updated

21/01/2024

Date data sharing statement initially provided

1/11/2018

Date results information initially provided

21/01/2024

Type of registration

Prospectively registered

Titles & IDs

Public title

BCT 1703 (DIAmOND): Patients with HER2-positive breast cancer that have progressed on prior trastuzumab therapy will be treated with a combination of tremelimumab and durvalumab, in combination with trastuzumab, to evaluate the efficacy of the combination treatment.

Scientific title

BCT 1703 (DIAmOND): An investigator-initiated, non-randomised, phase II study of combination CTLA-4 and PD-L1 blockade in advanced HER2-positive breast cancers who have progressed on prior trastuzumab-based therapy.

Secondary ID [1]

BCT 1703

Universal Trial Number (UTN)

Trial acronym

DIAmOND: Double Immune ActivatiON in her2-positive Disease

Linked study record

Health condition

Health condition(s) or problem(s) studied:

Advanced HER2-positive breast cancer

Condition category

Condition code

Cancer

Breast

Intervention/exposure

Study type

Interventional

Description of intervention(s) / exposure

TREMELIMUMAB 75 mg DOSE ER-POSITIVE COHORT AND ER-NEGATIVE COHORT
Induction phase (Weeks 1-16):
* Tremelimumab 75 mg every 4 weeks for 4 doses (intravenous);
* Durvalumab 1500 mg every 4 weeks for 4 doses (intravenous);
* Trastuzumab 2mg/kg every week for 16 weeks (intravenous).

Tremelimumab will be administered first. Durvalumab infusion will start approximately 1 hour after the end of tremelimumab infusion. The duration will be approximately 1 hour for each infusion. A 1 hour observation period is required after the first infusion of durvalumab and tremelimumab. If no clinically significant infusion reactions are observed during or after the first cycle, subsequent infusion observation periods can be at the Investigator’s discretion (suggested 30 minutes after each durvalumab and tremelimumab infusion).
Trastuzumab is given after Tremelimumab and Durvalumab.

Treatment phase (Weeks 17-52):
* Durvalumab 1120 mg every 3 weeks for 12 doses (intravenous); plus
* Trastuzumab 6 mg/kg every 3 weeks for 12 doses (intravenous).

Durvalumab will be administered first, followed by trastuzumab.

TREMELIMUMAB SINGLE 300 mg PRIMING DOSE COHORT
* Tremelimumab administered as a single 300 mg dose on Day 1, Cycle 1 (intravenous)
* Durvalumab 1120 mg administered with Tremelimumab on Day 1, Cycle 1 and continued every 3 weeks (intravenous) for up to 18 doses (1 year)
* Trastuzumab (intravenous):
- Loading dose of 8 mg/kg on Day 1, Cycle 1 if the last dose of trastuzumab or TDM-1 was greater than 6 weeks from the first dose of investigational study treatment
- 6 mg/kg every 3 weeks (with Durvalumab) for up to 18 doses (1 year).

All treatments will be administered by site staff trained in chemotherapy administration.

Intervention code [1]

Treatment: Drugs

Comparator / control treatment

None

Control group

Uncontrolled

Outcomes

Primary outcome [1]

Percentage of participants alive and progression free, determined by RECIST 1.1 for the Tremelimumab 75 mg dose ER-positive cohort and ER-negative cohort

Timepoint [1]

At 12 months from study registration.

Primary outcome [2]

Objective response rate by RECIST 1.1 for the Tremelimumab single 300 mg priming dose cohort.

Timepoint [2]

Assessed at each cycle (every3 weeks) until 12 months from study registration

Secondary outcome [1]

Safety and tolerability as documented according to NCI-CTCAE V4.03 and rates of serious adverse events (SAE) for the Tremelimumab 75 mg dose ER-positive cohort and ER-negative cohort

Timepoint [1]

Assessed at each cycle (every 4 weeks during induction phase; every 3 weeks in treatment phase) until 12 months from study registration.

Secondary outcome [2]

Median progression free survival (PFS) as determined by the investigator using RECIST 1.1 or death from any cause for the Tremelimumab 75 mg dose ER-positive cohort and ER-negative cohort

Timepoint [2]

Assessed at each cycle (every 4 weeks during induction phase; every 3 weeks in treatment phase) until first occurrence of disease progression.

Secondary outcome [3]

Objective response rate (ORR) Complete Response (CR) or Partial Response (PR) as best overall response using RECIST 1.1. or death from any cause for the Tremelimumab 75 mg dose ER-positive cohort and ER-negative cohort

Timepoint [3]

Assessed at each cycle (every 4 weeks during induction phase; every 3 weeks in treatment phase) until 12 months from study registration.

Secondary outcome [4]

Duration of response as defined by patients with objective responses (CR or PR as best overall response using RECIST 1.1) and first documentation of progression disease for the Tremelimumab 75 mg dose ER-positive cohort and ER-negative cohort

Timepoint [4]

Assessed at each cycle (every 4 weeks during induction phase; every 3 weeks in treatment phase) until first documentation of progressive disease. In the absence of documented progressive disease, follow up will be censored at date of last disease assessment;

Secondary outcome [5]

Time to treatment failure for the Tremelimumab 75 mg dose ER-positive cohort and ER-negative cohort

Timepoint [5]

From time of study registration to cessation of investigational study treatment for any reason, including death.

Secondary outcome [6]

Clinical benefit rate (CBR) as defined best overall response of CR, PR or SD disease lasting 24 weeks or longer for the Tremelimumab 75 mg dose ER-positive cohort and ER-negative cohort

Timepoint [6]

Assessed at each cycle (every 4 weeks during induction phase; every 3 weeks in treatment phase) until until first documentation of progressive disease.

Secondary outcome [7]

Progression Free Survivial by immune modified RECIST for the Tremelimumab 75 mg dose ER-positive cohort and ER-negative cohort

Timepoint [7]

Assessed at each cycle (every 4 weeks during induction phase; every 3 weeks in treatment phase) until 12 months from study registration.

Secondary outcome [8]

Median overall survival for the Tremelimumab 75 mg dose ER-positive cohort and ER-negative cohort.

Timepoint [8]

From time of study registration to death from any cause.

Secondary outcome [9]

12 month estimated overall survival. for the Tremelimumab 75 mg dose ER-positive cohort and ER-negative cohort

Timepoint [9]

From registration to 12 months after registration

Secondary outcome [10]

Percentage of participants alive and progression free, determined by RECIST 1.1 for the Tremelimumab single 300 mg priming dose cohort

Timepoint [10]

At 12 months from registration

Secondary outcome [11]

Median overall survival for the Tremelimumab single 300 mg priming dose cohort

Timepoint [11]

From time of study registration to death from any cause.

Secondary outcome [12]

Safety and tolerability as documented according to NCI-CTCAE V4.03 and rates of serious adverse events (SAE) for the Tremelimumab single 300 mg priming dose cohort

Timepoint [12]

Assessed at each cycle (every every 3 weeks) until 12 months from study registration.

Secondary outcome [13]

Clinical benefit rate (CBR) as defined by an objective response (OR) and/or stable disease for 24 weeks or more for the Tremelimumab single 300 mg priming dose cohort

Timepoint [13]

Assessed at each cycle (every 3 weeks) until until first documentation of progressive disease.

Secondary outcome [14]

Median progression free survival (PFS) as determined by the investigator using RECIST 1.1 or death from any cause for the Tremelimumab single 300 mg priming dose cohort

Timepoint [14]

Assessed at each cycle (every 3 weeks) until until first documentation of progressive disease.

Secondary outcome [15]

Duration of clinical benefit defined as time on study treatment for patients experiencing an objective response or stable disease for 24 weeks or more for the Tremelimumab single 300 mg priming dose cohort

Timepoint [15]

Assessed at each cycle (every 3 weeks) until until first documentation of progressive disease.

Eligibility

Key inclusion criteria

1) Written informed consent prior to performing any protocol-related procedures, including screening evaluations.

2) Written consent to biological material submission.

3) Female or Male, age >= 18 years.

4) Local histologically confirmed HER2-positive on a recent biopsy. This can be as per ASCO-CAP guidelines: IHC testing with a result of IHC 3+, or IHC 2+ISH testing with ERBB2-amplification as demonstrated by ratio ERBB2/centromeres >= 2.0 or mean gene copy number >= 6, unresectable loco-regional or metastatic breast cancer. HER2 status will be confirmed centrally retrospectively.

5) Locally assessed oestrogen receptor status based on mandatory biopsy. ER-positive is defined as >= 1% (any PR expression). ER-negative is defined as ER < 1% (any PR expression);

6) Must have previously received trastuzumab and pertuzumab in either the (neo)adjuvant or advanced disease setting where appropriate in the first line advanced setting.

7) Must have trastuzumab resistant disease, defined by any of the following:
* Demonstrated progression of disease while on-treatment with trastuzumab (monotherapy or combination-based therapy) or trastuzumab emtansine (TDM-1) for metastatic or unresectable loco-regional disease;
* Recurrence considered incurable while on adjuvant trastuzumab or within 12 months of completing adjuvant trastuzumab;
* Any number of prior lines of anti-HER2 therapy is acceptable. Patients who have not received any HER2 therapy in the advanced disease setting, must have received prior pertuzumab in the neo/adjuvant setting;
* Progression/recurrence must have been demonstrated by radiological or clinical assessment.

8) If a participant has received a subsequent anti-HER2 therapy, she/he must also have progressed on the subsequent therapy. Progression must have been demonstrated by radiological or clinical assessment.

9) Body weight > 30 kg.

10) Able to commence treatment within 7 days of registration.

11) Availability of 2 FFPE tumour biopsies or 15-20 slides for retrospective central testing of HER2 positivity, assessment of PD-L1 status, TIL level, and for translational research taken from unresectable loco-regional or metastatic disease obtained =< 1 year prior to enrolment. Alternatively, new tissue material from a recently obtained surgical or diagnostic biopsy can be submitted. Tissue obtained for the biopsy must not have been previously irradiated.
Note: Submission of a tumour biopsy for central pathology review and translational research is mandatory for this study, however central confirmation of HER2-positivity is not required for eligibility. At least two core biopsies should be available.

12) Measurable disease per RECIST v1.1.

13) Have left ventricular ejection fraction (LVEF) of >= 50% or >= institution lower limit of normal (LLN) as assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scan performed within 3 months of registration.

14) Participant has ECOG 0-1.

15) Life expectancy > 3 months.

16) Adequate organ and marrow function as defined below:
* Haemoglobin >= 9.0 g/dL;
* Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (> 1500 per mm^3);
* Platelet count >= 75 x 10^9/L (> 75,000 per mm^3)
* Serum bilirubin =< 1.5 x institutional upper limit of normal (ULN). In the case of known Gilbert’s syndrome, a higher serum total bilirubin (< 2 x ULN) is allowed;
* AST (SGOT)/ALT (SGPT) =< 2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be =< 5 x ULN;
* Creatinine =< 1.5 x ULN or serum creatinine clearance > 40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance.
* International Normalized Ratio (INR) or Prothrombin Time (PT) =< 1.5 x ULN unless participant is receiving anticoagulant therapy as long as INR, PT or APTT is within therapeutic range of intended use of anticoagulant.

17) Agrees to use of condoms and non-hormonal IUD from screening to 7 months after the last dose of trastuzumab, or 180 days after the last dose of durvalumab + tremelimumab combination therapy, or 90 days after the last dose of durvalumab monotherapy (whichever is longest).

18) Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrhoeic for 12 months without an alternative medical cause. The following age-specific requirements apply:
* Women < 50 years of age would be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
* Women >= 50 years of age would be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses > 1 year ago, had chemotherapy-induced menopause with last menses > 1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).

19) Willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations during both the treatment and follow-up phases.

Minimum age

18 Years

Maximum age

No limit

Sex

Both males and females

Can healthy volunteers participate?

Key exclusion criteria

1) Previous history of primary HER2 non-amplified invasive breast cancer (of different subtype) in the last 3 years.

2) Participation in another clinical study with an investigational product during the last 4 weeks before enrolment.

3) Prior cytotoxic treatment less than 2 weeks before the planned first dose of Durvalumab and Tremelimumab.

4) Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab or an anti-CTLA-4, including tremelimumab.

5) No FFPE material to centrally assess HER2-positivity, PD-L1 expression and TIL levels.

6) Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of investigational study treatment. Note: Local surgery of isolated lesions for palliative intent is acceptable.

7) Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) >=470 ms calculated from a single ECG.

8) Female participants who are pregnant or breastfeeding or male or female participants of reproductive potential who are not willing to employ effective birth control from screening to 7 months after the last dose of trastuzumab, or 180 days after the last dose of durvalumab + tremelimumab combination therapy, or 90 days after the last dose of durvalumab monotherapy – whichever is longest will apply.

9) Interstitial lung disease.

10) History of, or active drug-related pneumonitis requiring treatment with steroids.

11) Patients with symptomatic central nervous system (CNS) disease or known leptomeningeal disease are not eligible except for treated asymptomatic CNS metastases, provided that all of the following criteria are met:
* Only supratentorial and cerebellar metastases allowed (i.e., no metastases to midbrain, pons, medulla, or spinal cord).
* No ongoing requirement for corticosteroids as therapy for CNS disease.
* No ongoing generalized or complex partial seizures.
* No stereotactic radiation or whole brain radiotherapy within 14 days prior to study treatment. No evidence of interim progression (clinical or radiological) between the completion of prior CNS-directed therapy and commencement of study. Repeat CNS imaging should be done as clinically indicated.
* Note: Patients with new asymptomatic CNS metastases detected at the screening scan must receive radiation therapy and/or surgery for CNS metastases. Following treatment, these patients may be eligible without the need for an additional brain scan prior to enrollment, if all other criteria are met.
* Patients who have CNS metastases deemed too small to treat and detected at screening must demonstrate stability in size (=/<5mm) on a follow-up scan minimum of 3 weeks later.

12) Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for > 2 weeks prior to randomization.

13) Leptomeningeal disease.

14) Symptomatic pleural effusion, pericardial effusion, or ascites requiring frequent drainage (< 2 weekly).

15) History of clinically significant or uncontrolled cardiac disease, including congestive heart failure (New York Heart Association functional classification > 3), angina, myocardial infarction or ventricular arrhythmia.

16) Previous severe hypersensitivity reaction to treatment with another monoclonal antibody.

17) Active or uncontrolled infection CTCAE V4.03 grade 2 or higher.

18) Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab or tremelimumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid.

19) Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhoea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.

20) Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g. colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this criterion:
* Patients with vitiligo or alopecia;
* Patients with hypothyroidism (e.g. following Hashimoto syndrome) stable on hormone replacement;
* Any chronic skin condition that does not require systemic therapy;
*Patients with celiac disease controlled by diet alone.

21) History of primary immunodeficiency.

22) History of allogeneic organ transplant.

23) Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.

24) Chemotherapy, radiotherapy, and/or biological cancer therapy (except trastuzumab and endocrine therapy) within 2 weeks prior to the first study dose and has not recovered to CTCAE V4.03 grade 1 or better from adverse events (except alopecia grade 2). Prior chemotherapy induced neuropathy should be grade 2 or better.

25) Any unresolved toxicity NCI CTCAE Grade >= 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab or tremelimumab may be included only after consultation with the Study Chair and the Director/Deputy Director of Research.

26) Live vaccines within 30 days prior to the first dose of investigational study treatment and during investigational study treatment.

27) Previous or concomitant invasive malignancy (except breast cancer). The exceptions are:
* participants with non-breast malignancy >= 3 years ago, treated with curative intent and without evidence of recurrence;
* basal or squamous cell carcinoma of the skin;
* in situ carcinoma without invasion (includes in situ breast carcinoma).

28) Any condition that, in the opinion of the investigator, would interfere with evaluation of investigational study treatment or interpretation of participant safety or study results.

Study design

Purpose of the study

Treatment

Allocation to intervention

Non-randomised trial

Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)

Methods used to generate the sequence in which subjects will be randomised (sequence generation)

Masking / blinding

Open (masking not used)

Who is / are masked / blinded?

Intervention assignment

Parallel

Other design features

Phase

Phase 2

Type of endpoint/s

Safety/efficacy

Statistical methods / analysis

Recruitment

Recruitment status

Active, not recruiting

Date of first participant enrolment

Anticipated

1/11/2018

Actual

22/11/2018

Date of last participant enrolment

Anticipated

30/06/2023

Actual

31/12/2023

Date of last data collection

Anticipated

31/12/2024

Actual

Sample size

Target

Accrual to date

Final

Recruitment in Australia

Recruitment state(s)

NSW,QLD,SA,TAS,WA,VIC

Recruitment hospital [1]

Austin Health - Austin Hospital - Heidelberg

Recruitment hospital [2]

Bendigo Health Care Group - Bendigo Hospital - Bendigo

Recruitment hospital [3]

Fiona Stanley Hospital - Murdoch

Recruitment hospital [4]

Flinders Medical Centre - Bedford Park

Recruitment hospital [5]

Mater Private Hospital - South Brisbane

Recruitment hospital [6]

Peter MacCallum Cancer Centre - Melbourne

Recruitment hospital [7]

Royal Hobart Hospital - Hobart

Recruitment hospital [8]

St George Hospital - Kogarah

Recruitment hospital [9]

Sunshine Coast University Hospital - Birtinya

Recruitment hospital [10]

Westmead Hospital - Westmead

Recruitment hospital [11]

Lake Macquarie Private Hospital - Gateshead

Recruitment postcode(s) [1]

3084 - Heidelberg

Recruitment postcode(s) [2]

3550 - Bendigo

Recruitment postcode(s) [3]

6150 - Murdoch

Recruitment postcode(s) [4]

5042 - Bedford Park

Recruitment postcode(s) [5]

4101 - South Brisbane

Recruitment postcode(s) [6]

3000 - Melbourne

Recruitment postcode(s) [7]

7000 - Hobart

Recruitment postcode(s) [8]

2217 - Kogarah

Recruitment postcode(s) [9]

4575 - Birtinya

Recruitment postcode(s) [10]

2145 - Westmead

Recruitment postcode(s) [11]

2290 - Gateshead

Funding & Sponsors

Funding source category [1]

Other Collaborative groups

Name [1]

Breast Cancer Trials

Address [1]

PO Box 283
The Junction NSW 2291

Country [1]

Australia

Primary sponsor type

Other Collaborative groups

Name

Breast Cancer Trials

Address

PO Box 283
The Junction NSW 2291

Country

Australia

Secondary sponsor category [1]

None

Name [1]

Address [1]

Country [1]

Ethics approval

Ethics application status

Approved

Ethics committee name [1]

Peter MacCallum Cancer Centre HREC

Ethics committee address [1]

Ethics Committee Secretariat
Peter MacCallum Cancer Centre
Locked Bag 1, A/Beckett Street
Victoria 8006

Ethics committee country [1]

Australia

Date submitted for ethics approval [1]

03/07/2018

Approval date [1]

20/09/2018

Ethics approval number [1]

HREC/18/PMCC/126

Summary

Brief summary

This study aims to find out if the combination of trastuzumab (anti-HER2 therapy) with durvalumab (PD-L1 inhibitor) and tremelimumab (CTLA4 inhibitor) will reactivate anti-tumour immune response and improve clinical outcomes in trastuzumab-resistant, advanced HER2-positive breast cancer.

Who is it for?
You may be eligible for this study if you are 18 years or older, male or female, and have HER2-positive metastatic or incurable breast cancer that has progressed on previous trastuzumab treatment.

Trial Details.
Up to 4 weeks before starting study treatment, all participants will have either a CT Scan, MRI, or PET with dedicated CT Scan, provide a research tumour biopsy of the cancer (taken within 1 year of starting the study) and research blood tests.

TREMELIMUMAB 75 mg DOSE ER-POSITIVE AND ER-NEGATIVE COHORTS:
Study treatment takes place in 2 phases:
1) Induction Phase (weeks 1-16); and
2) Treatment Phase (weeks 17-52).

Induction Phase
During the Induction Phase, participants will receive:
1) 4 doses of durvalumab (1 dose every 4 weeks), administered intravenously;
2) 4 doses of tremelimumab (1 dose every 4 weeks), administered intravenously;
3) 16 doses of trastuzumab (1 dose every week), administered intravenously.

Treatment Phase
Participants will receive durvalumab and trastuzumab every 3 weeks for 12 doses (total 36 weeks). Tremelimumab will not be given.

A research blood sample will be taken every 9 weeks, before each dose of study treatment.

TREMELIMUMAB SINGLE 300 mg PRIMING DOSE COHORT
One cycle is 3 weeks (maximum of 18 cycles).
1) Tremelimumab 300 mg Day 1, Cycle 1 only (1 dose only)
2) Durvalumab 1120 mg Day 1, Cycle 1 then every 3 weeks for up to 1 year (18 doses)
PLUS
3) Trastuzumab:
* 6 mg/kg Day 1, Cycle 1 then every 3 weeks for up to 1 year (18 doses)
* Loading dose of 8 mg/kg Cycle 1 Day 1 if > 6 weeks since the last trastuzumab or TDM-1 dose.

Research blood samples will be collected at Week 10 and Week 16.

For all cohorts:
Oestrogen-receptor-positive patients will also start or continue endocrine therapy (aromatase inhibitor and/or GnRH agonist).

Two core biopsies, if feasible, will be taken from the same site as the initial biopsy about 3 weeks after starting study treatment.

During the study heart function tests (ECHO or MUGA) will be performed every 3 months as per standard of care, or as clinically indicated.

Participants will be clinically assessed before each study treatment.

The full length of treatment is 52 weeks (1 year). After completing study treatment, patients will be followed every 3 months by either clinic visits or via telephone.

Trial website

www.breastcancertrials.org.au

Trial related presentations / publications

Public notes

Breast Cancer Trials formerly known as Australia & New Zealand Breast Cancer Trials Group.

Contacts

Principal investigator

Name

A/Prof Sherene Loi

Address

Division of Cancer Medicine, Department of Medical Oncology
Peter MacCallum Cancer Centre
Locked Bag 1, A'Beckett Street
MELBOURNE VIC 8006

Country

Australia

Phone

+61 3 8559 5935

Fax

corinna.beckmore@bctrials.org.au

Contact person for public queries

Name

Ms Corinna Beckmore

Address

BCT
PO Box 283
The Junction NSW 2291

Country

Australia

Phone

+61 2 4925 5235

Fax

corinna.beckmore@bctrials.org.au

Contact person for scientific queries

Name

A/Prof Sherene Loi

Address

Division of Cancer Medicine, Department of Medical Oncology
Peter MacCallum Cancer Centre
Locked Bag 1, A'Beckett Street
MELBOURNE VIC 8006

Country

Australia

Phone

+61 3 8559 5935

Fax

corinna.beckmore@bctrials.org.au

Data sharing statement

Will individual participant data (IPD) for this trial be available (including data dictionaries)?

Yes

What data in particular will be shared?

Anonymised Individual Patient Data (IPD) collected during the trial.

When will data be available (start and end dates)?

Data will be made available for request after publication of the main/final study results; no end date.

Note that there may be additional circumstances preventing BCT from sharing requested data as outlined in the BCT Data Sharing Guidelines .

Available to whom?

Researchers who submit a research proposal and BCT Data Request Application, which is assessed by BCT to have appropriate scientific value. Refer to the BCT Data Sharing Guidelines

Available for what types of analyses?

To achieve the aims in the approved proposal.

How or where can data be obtained?

Subject to approval by Breast Cancer Trials concept@bctrials.org.au (refer to BCT Data Sharing Guidelines).

What supporting documents are/will be available?

Other

'Other' documents specified

Please refer to BCT Data Sharing Guidelines attached below. Data requestors will be required to submit a research proposal, along with the BCT Data Request Application (contact concept@bctrials.org.au to obtain this form), to document the acceptability of the research question and the qualifications of the requestor(s). The exact supporting documents provided for the project will be determined in the application and review/approval process.

How or where can supporting documents be obtained?

Type [1]

Other

Citation [1]

Link [1]

https://researchdata.edu.au/an-investigator-initiated-1703-diamond/2836020

Email [1]

Other [1]

Attachment [1]

/Steps11and12/362077-(Uploaded-11-01-2024-10-52-25)-Study-related document.pdf

Summary results

Have study results been published in a peer-reviewed journal?

Other publications

Have study results been made publicly available in another format?

Results – basic reporting

Results – plain English summary

Trial Review